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Aim. To evaluate characteristics of esophageal involvement in scleroderma. Methods. The study was prospective and concerned
194 patients with a deﬁnite systemic sclerosis. Gastroesophageal endoscopy and esophageal manometry were performed in all the
cases. Results. Symptoms were present in 118 cases (60.8%); they were signs of GERD or dysphagia, respectively, in 94 (48.4%)
and 91 patients (46.9%). Reﬂux esophagitis was found in 73 cases (37.6%); it was mild or moderate in 47 cases (24.2%) and
severe or complicated in the remaining cases. Manometry revealed a lower esophageal sphincter incompetence and esophageal
motor disorders, respectively, in 118 (60.8%) and 157 cases (80.9%). Presence of these late was not related to age, duration, or
skin extension of the disease, but with clinical complaint and/or mucosal damage. Conclusion. Esophageal involvement is frequent
during scleroderma. Manometry is the most sensible examination and could be a screening procedure.
1.Introduction
Involvement of esophagus is common in systemic sclerosis
(SSc) [1, 2]. It consists mainly of esophageal motor disorders
(EMDs) that are responsible for all clinical manifestations
as well as gastroesophageal reﬂux disease (GERD) and its
complications [2–4]. The factors which aﬀect occurrence of
esophageal involvement in SSc are discussed [5–7].
2. Aim
The aim of this study was to evaluate clinical, endoscopic,
and manometric features of esophageal involvement in
patients with scleroderma through a large cohort of patients
with SSc.
3. Patientsand Methods
The recruitment was prospective, at a single center, and
concerned 194 consecutive patients with SSc diagnosed
according to the American College of Rheumatology criteria
[8], over a period of 20 years (April 1988–December 2008).
Mixed connective tissue disease and forms associated with
diabetes mellitus were excluded.
The patient’s mean age was 40.4 ± 13.5 years (11–73
years), gender was female in 170 cases (87.6%), and average
duration of the disease was 6.8 ± 7,5 years (6 months–
32 years). According to LeRoy’s classiﬁcation of generalized
scleroderma [9], a limited cutaneous form was observed in
158 cases (81.4%) and a diﬀuse form in 36 cases (18.5%).
All the patients underwent a standardized medical
card, an upper gastrointestinal endoscopy, and a standard
esophageal manometry during the same visit, before initiat-
ing any antisecretory treatment.
Data collected included patient’s age, gender, clinical
characteristic of the disease (duration, skin extension), and
presence or absence of symptoms of GERD (heartburn
and/or acid regurgitation) and/or dysphagia. Each symptom
w a sgra d e do nas c a l ef r o m0t o3b yi n t e n s i ty( 0= absent, 1 =
mild, could be ignored by the patient, 2 = moderate, could
not be ignored, but had no eﬀect on daily life activities, 3 =
severe or incapacitating, aﬀecting daily life activities) and by
frequency (0 = absent or less than one per month; 1 = less
than 1 per week; 2 = several times per week; 3 = every day)
[10]. Symptoms where then categorized as mild for a total
score less than, or equal to six, moderate for a total score
of seven to twelve and severe for a total score greater than2 ISRN Rheumatology
Table 1: Factors linked with the presence or absence of esophageal symptoms.
Esophageal symptoms
Presence (n = 118) Absence (n = 76) P
Limited/diﬀuse form 91/27 67/9 0.05
Duration of the disease (years) 7.2 ± 75 ± 7.8 0.22
Reﬂux esophagitis 60 (50.8%) 13 (17.1%) <0.001
EMDs 109 (92.3%) 48 (63.1%) <0.001
EMDs: esophageal motor disorders.
Table 2: Factors linked with presence or not of reﬂux esophagitis.
Reﬂux esophagitis
Presence (n = 73) Absence (n = 121) P
Limited /diﬀuse form 58/15 100/21 0.57
Duration of the disease (years) 6.9 ± 6.9 6.6 ± 7.6 0.57
Esophageal symptoms 60 (82.2%) 58 (47.9%) <0.001
EMDs 70 (95.9%) 87 (71.9%) <0.001
EMDs: esophageal motor disorders.
twelve, or when one symptom was considered incapacitating
every day (score = 9).
Upper gastrointestinal endoscopy was used to identify
and stage reﬂux esophagitis according to the Los Ange-
les classiﬁcation [11]. Manometry was performed with a
four-channel infusion probe (distilled water infusion rate:
0.5mL/mn). The procedure was used after discontinuation
of medication that might aﬀect esophageal motility at least
72h before exam and following a 12-hour fast. Normal
manometric values were established in our laboratory using
a control population of 24 healthy subjects matched for age
and gender (gender ratio of 0.2, mean age of 41.7 ± 10.7
years, age range: 29–60 years).
Student’s t-test, chi2, and a reduced standard deviation
(SD) test were used as appropriate to compare means and
percentages. The level of signiﬁcance was P<0.05.
4. Results
Esophageal symptoms were found in 118 patients (60.8%)
with GERD symptoms observed in 94 cases (48.4%) and
dysphagia in 91 cases (46.9%). Both type of symptoms were
present in 67 cases (34.5%). The clinical complaint was
considered mild in 74 cases (38.1%), moderate in 27 cases
(13.9%), and severe in 17 cases (8.7%).
Reﬂux esophagitis was found in 73 cases (37.6%). It was
mild or moderate (stage A or B LA) in 47 cases (24.2%),
severe (stage C or D LA) in 7 cases (3.6%), and complicated
by stenosis and/or Barrett esophagus in 19 cases (9.8%). No
case of esophageal ulcer or adenocarcinoma was observed.
Manometry was disrupted in 167 cases (86%). There was
a hypotensive lower esophageal sphincter (LES) pressure in
118 patients (60.8%) and EMDs in 157 cases (80.9%); both
disorders were present in 108 cases (55.6%). A hypotensive
upper esophageal sphincter pressure was present in 14
patients (7.2%). EMDs were severe, of aperistalsis type,
in 118 cases (60.8%), and a low pressure wave amplitude
was observed in 36 cases (18.5%) and an uncoordinated
peristalsis in 25 cases (12.9%). EMDs were extended to lower
two-thirds of the esophagus in 137 cases (70.6%).
Presence of esophageal symptoms was not related with
duration of the SSc, but it was signiﬁcantly more frequent
in diﬀuse form of the disease and in those with esophageal
mucosal lesions and/or EMDs (Table 1).
Presence of reﬂux esophagitis was not linked with
subtype or duration of the disease, but it was statistically
more frequent in the symptomatic population and was
also more observed in forms with EMDs. Nevertheless, it
remained silent in 13 cases (17.8%) (Table 2).
EMDs were common in all forms of the disease,
regardless of age, gender, degree of skin involvement, or
duration of the disease. However, they were signiﬁcantly
more often present in cases with clinical complaints and/or
reﬂux esophagitis, but they remained asymptomatic in 48
cases (30.5%) (Table 3).
5. Discussion
Overall incidence of esophageal symptoms during SSc has
been estimated to be between 42% and 79% [2, 3, 12–16].
The complaint is related to signs of reﬂux in 14–71% of
patients and dysphagia in 24–82% of cases [2, 5, 15, 17, 18],
both symptoms being present in 29%–66% of cases [15, 19].
In our series, overall incidence of symptoms was 61%, signs
of reﬂux and dysphagia were, respectively, near 48% and
47%; both were present in more than 34% of cases. Presence
of esophageal complaint was not related to the duration of
the disease in the literature [5, 7] and in this work. Their
relationship with the subtype of SSc is more controversial.
Thus, for Akesson and Wollheim [5], Koshino et al. [6], and
Bassotti et al. [17], presence of symptoms was not related to
the subtype of SSc, but in our series, they were signiﬁcantlyISRN Rheumatology 3
Table 3: Parameters linked with presence or not of EMDs.
Esophageal motor disorders
Presence (n = 157) Absence (n = 37) P
Mean age (years) 40.7 ± 13.5 39.4 ± 13.5 0.59
Male/female 18/139 6/31 0.6
Limited/diﬀuse form 125/32 33/4 0.17
Duration of the disease (years) 6.8 ± 7.2 6.2 ± 7.9 0.65
Esophageal symptoms 109 (69.4%) 9 (24.3%) <0.001
Reﬂux esophagitis 70 (44.6%) 3 (8%) <0.001
more frequent in diﬀuse form of the disease. Esophageal
complaint was also more frequent and more severe in case
of presence of reﬂux esophagitis in our experience as well as
in literature [15, 20].
Even if, for most authors, there is no correlation between
presenceofesophagealsymptomsandpresenceofEMDs[13,
21], a link was, however, established between their severity
a n dp r e s e n c eo fE M D s[ 6, 7, 22]. In this study, symptoms
were signiﬁcantly more frequent in presence of esophageal
dysmotility and are, therefore, a simple warning sign that
s h o u l dp r o m p ts e a r c ho fE M D sb ym a n o m e t r y .
Prevalence of reﬂux esophagitis has averaged between
30% and 40%. In fact, it is variously reported between
3.2% and 60% [15, 16, 18, 20, 23, 24]. The highest rates
were reported by Zamost et al. [20] and Hendel [23]a n d
are probably due to the fact that these patients on a large
catch of anti-inﬂammatory drugs. The lowest, prevalence
(3.2%), reported by Poirier in a surgical series concerned
forms complicated by stenosis [13]. In an autopsy series of
58 patients with SSc, D’Angelo found erosive esophagitis in
40% of cases [25].
Complicated forms of reﬂux esophagitis were also more
frequent in patients with SSc than in the general population
[18]. Reﬂux esophageal stenosis is reported in 3–40%
of cases depending on the series [13, 15, 26–28], while
Barrett esophagus in 6.8–37% [13, 15, 26–28] or even 71%
of cases [29] and, more rarely, ulcer of esophagus [16].
Adenocarcinoma of esophagus would be also more frequent
in SSc, it rate reaches 7% for Katzka et al. [26]a n dR e c h t
et al. [30] but, Segel relates only one case in a large series
of 680 patients with SSc followed for 11 years [31]. In our
series, reﬂux esophagitis was observed in nearly 38% of cases
and was complicated by stenosis and/or Barrett esophagus in
10% of cases.
Esophageal dysmotility of SSc is characterized by a
LES hypotonia and EMDs respecting the cervical segment
of esophagus. In the recent series, overall frequency of
manometric abnormalities is very high, 70%–96% [16, 19,
31–34]. LES hypotonia is present in more than 50% of cases
and is, in general, associated with EMDs. These latter are
notedinmorethan60%ofcases.Thereisalowpressurewave
amplitude in 48%–81% of cases [1, 18], an uncoordinated
peristalsis in 40%–91% [18, 34, 35], and an aperistalsis in
23%–52% [18, 32, 33] of patients.
Relationship between presence of EMDS and subtype of
SSc is controversial. For some authors, there is no parallelism
between frequency or severity of EMDs and subtype of SSc
[2, 32, 36–38]. For others, they would be more severe in
diﬀuse form of scleroderma [5, 6, 39], yet in other works,
EMDs are both more frequent and more severe in the
diﬀuse SSc [14, 16, 17, 34]. In our series, degree of skin
involvement did not signiﬁcantly inﬂuence frequency or
severity of manometric disorders.
Moment occurrence of EMDs would be very early.
Indeed, they occur within one year after diagnosis of the
disease in the work of Hostein et al. [21]a n dH a m e l -
Roy et al. [40], even at the stage of isolated Raynaud’s
phenomenon, before the onset of skin involvement [21, 38].
The subsequent evolution is more controversial. Frequency
and severity of the disorder increase with disease duration
[23, 32] for some authors, rather not for others [16, 19].
For most authors, presence of esophageal symptoms
is not a good indicator of those of EMDs [2, 6, 14, 20,
35, 41]. Thus, in Lock’s series, 25% of EMDs remained
asymptomatic,and,conversely,50%ofsymptomaticpatients
had a normal manometry [2]. The existence of symptoms
had a negative predictive value of 50% and a positive
predictive value of 62%. For this author, this means a weak
association and justiﬁes manometry in the assessment of any
SSc. In other series, severe EMDs remained asymptomatic in
21%–40% of cases and the presence of symptomatic patients
with normal manometry is also often reported [15, 17, 39].
For Sj¨ ogren, this discrepancy may be related to the existence
of visceral autonomic neuropathy [4]. However, there seems
to be a link between severity of symptoms and existence
of esophageal dysmotility [6, 7, 41]. In our experience,
although manometry was signiﬁcantly more often and more
severely impaired in patients with esophageal complaint,
EMDS remained asymptomatic in 48 cases (30.5%).
EMDS are also a major predictor factor of occurrence of
reﬂux esophagitis [4, 16, 17, 24, 37]. Peristalsis is never or
rarely normal in this case as well for us than in published
series [15, 20].
6. Conclusion
Esophagus involvement is very frequent during scleroderma.
It occurs early and comprises a reﬂux esophagitis in more
than one third of cases. Esophageal manometry is useful in
all forms of the disease, more particularly in asymptomatic
populationandwithoutendoscopiclesions.Atanearlystage,
it allows detection of EMDs which are a strong marker of4 ISRN Rheumatology
the disease and at deﬁnite form of the disease, and it assesses
risk of occurrence of reﬂux esophagitis. Then, manometry
could be a screening procedure in scleroderma.
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